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Background: Quality of life (QoL) is routinely assessed and evaluated in medical research. However, in Japan, there
is a lack of solid cutoff criteria for evaluating QoL improvement in chronic noncancer pain management. The
present study was conducted to identify the minimal clinically important change (MCIC) of the Japanese version of
EuroQol-5D 3L(EQ-5D) utility score and numeric rating scale (NRS) with an emphasis on chronic noncancer pain.
Methods: The data source for this post hoc research was the post-marketing surveillance (PMS) data for a
tramadol/acetaminophen combination tablet, which was previously conducted in real-world settings. The
parameters extracted from the PMS data were sociodemographic characteristics, NRS, EQ-5D, and dichotomous
physician’s global impression of treatment effectiveness (PGI). The optimal cutoff points of MCIC for EQ-5D
utility and NRS scores were evaluated using receiver operating characteristics (ROC) analysis. An anchor-based
approach using PGI was applied.
Results: Data of 710 patients with chronic noncancer pain were extracted from the PMS database. The NRS
score decreased by 2.7 (standard deviation, 2.3) points, whereas the EQ-5D score increased by 0.16 (0.20) points
at 4 weeks from baseline. The changes from baseline in NRS and EQ-5D were significantly correlated (r = 0.53,
p < 0.001). The estimated optimal cutoff points of MCIC for EQ-5D and NRS were 0.10 and −2.0 points,
respectively. The area under the curve of ROC was > 0.80 in both analyses.
Conclusion: These results demonstrated novel cutoff criteria for the Japanese version of EQ-5D, focusing on
patients with chronic noncancer pain. The obtained criteria were fairly consistent and can be confidently
utilized as an evaluation tool in medical research on chronic noncancer pain in Japan, with additional
functionality and usability for QoL assessment in pain management practice.
Trial registration: The data source of this post hoc research was a PMS study with the identifier number
UMIN000015901 at umin.ac.jp, UMIN clinical trial registry (UMIN-CTR).
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Chronic noncancer pain is one of the most common
harmful experiences worldwide. It is not only respon-
sible for impaired quality of life (QoL) and active daily
life but is also associated with high costs because of long
medical treatment and loss of work productivity [1, 2].
Among the Japanese population, 22.9 % suffer from
chronic pain reported by numeric rating scale (NRS) to
be a severity ≥ 5 and longer than 3 months duration. Of
these patients, 55.9 % reported hospital visits due to
pain, and 45.2 % of patients who had a hospital visit re-
ported dissatisfaction with the care they received [3].
Health-related quality of life (HRQOL) instruments,
particularly the EuroQol-5D (EQ-5D) [4], are widely
used in health surveys and medical research. Lamers
et al. showed the association between lower level EQ-
5D utility scores and efficiency loss/absenteeism in in-
dividuals with low back pain [5]. Kovacs et al. pointed
out a notable association between pain, disability, and
QoL in patients with low back pain; however, they also
postulated that clinically relevant improvements in
pain severity exerted much less influence than did im-
provements in disability and QoL. This suggested that
disability and/or QoL should be assessed when evalu-
ating the effect of any form of treatment for low back
pain [6]. In addition, these results suggested the
importance of identifying target improvements in
patients’ HRQOL and pain intensity and their association
with success of chronic noncancer pain treatment. Several
reports have suggested a minimal clinically important
change (MCIC) of EQ-5D utility score in the treatment of
low back pain [7–9]; moreover, several studies on muscu-
loskeletal pain have reported MCIC of a pain intensity
score [10–13]. However, no study has reported the MCIC
of the Japanese version EQ-5D with an emphasis on
chronic noncancer pain.
Although QoL assessment has become common in
medical research in Japan, its interpretation still remains
unclear. Suka et al. reported that the mean difference of
EQ-5D utility scores between patients with low back
pain and healthy volunteers was 0.09 in Japanese popula-
tion [14], but MCIC was not evaluated in this study. A
solid, methodologically sound, Japanese-specific MCIC
of the EQ-5D utility score is essential for QoL assess-
ment using the EQ-5D questionnaire in real-world man-
agement of chronic noncancer pain.
In the present study, we conducted a retrospective
post hoc analysis to identify the optimal cutoff point
(OCP) MCIC of the Japanese version EQ-5D utility
score as well as the NRS score and to evaluate the as-
sociation between the two scores using data from a
multicenter post-marketing surveillance (PMS) of a
tramadol/acetaminophen combination tablet in pa-
tients with chronic noncancer pain.Methods
Data source
In this study, a post hoc data analysis was conducted
using PMS data (data cutoff: September 2014, Identifier:
UMIN000015901) collected from 1,316 patients with
moderate chronic noncancer pain who were treated with a
tramadol/acetaminophen combination tablet (tramadol
37.5 mg and acetaminophen 325 mg per tablet) in routine
clinical practice [15]. PMS is a drug-specific registry that
evaluates risks and benefits of a specific product. The PMS
protocol was reviewed by internal review board members,
including the ethical point of view, and was approved by
the Japan Pharmaceuticals and Medical Devices Agency,
Tokyo (https://www.pmda.go.jp/english/index.html). The
PMS was conducted under the Japanese regulation
(Ministry of Health, Labour and Welfare Ministerial
Ordinance No. 171) of good post-marketing study practice
(GPSP). All patients registered under the PMS received
tramadol/acetaminophen combination tablets for up to
52 weeks based on regulatory approved label information
in Japan. In Japan, tramadol/acetaminophen combination
is indicated for patients with chronic noncancer pain that
is unrelieved by non-opioid analgesic medication. The
daily dose was determined at the discretion of each re-
sponsible practicing investigator. No restrictions were
placed on concomitant medications or physical and psy-
chological therapies.Measures and dataset
The sociodemographic data and name of the causal dis-
ease of pain were retrieved from PMS data. We also re-
trieved the NRS (0 to 10 points, 0: have no pain and 10:
worst imaginable pain) for severity of the pain experienced
by patients in the previous 24 h, the Japanese version of
EQ-5D 3L [16] as patient-reported outcome measures,
and the dichotomous physician’s global impression of
treatment effectiveness (PGI; discrete choice of “effective”
or “not effective”). The EQ-5D scale contains five dimen-
sions assessing “mobility,” “self-care,” “usual activities,”
“pain/discomfort,” and “anxiety/depression.” Each dimen-
sion has three levels: “no problem,” “some problem,” and
“extreme problem.” The collected EQ-5D scale was trans-
lated into a global utility score by using a Japanese version
of time trade-off value set. Higher EQ-5D global scores
represent better QoL. While the original study collected
data up to 52 weeks, relatively a small number of partici-
pant responded at 52 weeks. Since we intended to esti-
mate the MCIC without any imputation of missing data,
this might cause biased results. Therefore, because of the
applicability of our results to the clinical practice and the
sample size, the MCICs were estimated based on using
data at week 4. Patients with complete EQ-5D, NRS, and
PGI at baseline and Week 4 were included in the analyses.




Male 710 272 (38.3)
Female 710 438 (61.7)
Age (years: mean [SD]) 710 66.7 [14.4]
BMI (kg/m2: mean [SD]) 372 23.4 [3.8]
Disease Duration (years: mean [SD]) 499 2.0 [3.4]
Baseline NRS (score: mean [SD]) 710 7.1 [1.9]
Baseline EQ-5D (score: mean [SD]) 710 0.5 [0.2]
Major the causal disease of pain (multiple allowed)
Osteoarthritis 710 182 (25.6)
Lumbago 710 285 (40.1)
Rheumatoid arthritis 710 29 (4.1)
Neck, shoulder, and arm syndrome 710 44 (6.2)
Postherpetic neuralgia 710 54 (7.6)
Periarthritis scapulohumeralis 710 46 (6.5)
Spinal stenosis 710 61 (8.6)
Disk herniation 710 30 (4.2)
Others 710 233 (32.8)
Site of pain
Head 710 26 (3.7)
Lumbar region 710 374 (52.7)
Lower extremity 710 264 (37.2)
Cervical region 710 90 (12.7)
Shoulder 710 101 (14.2)
Upper extremity 710 54 (7.6)
Back 710 59 (8.3)
Chest/abdomen 710 34 (4.8)
Hand/foot 710 55 (7.7)
BMI denotes body mass index, NRS numeric rating scale, EQ-5D EuroQol 5D,
SD standard deviation
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Patient demographics were evaluated using descriptive
statistics; categorical data were summarized by frequency
and proportion, continuous data were summarized as
mean with standard deviation (SD), median, maximum,
and minimum.
A linear regression model was applied to evaluate cor-
relation (r) and slope (β) between absolute changes from
baseline of EQ-5D (dEQ-5D) and NRS (dNRS). The
MCIC of EQ-5D and NRS at Week 4 were evaluated
using receiver operating characteristic (ROC) curve an-
chored by PGI at Week 4. An area under the ROC curve
(AUC) > 0.70 was considered as a sufficient level of pre-
diction to identify MCIC [17]. MCIC, the OCP of ROC,
was determined using the maximal point of the sum of
sensitivity and specificity [18]. Subsequently, the ratio of
patients who achieved MCIC of EQ-5D and NRS was
calculated. In addition, logistic regression analysis was per-
formed to investigate the influence of dNRS and dEQ-5D
on PGI judgment. Standardized (Z score) dNRS and dEQ-
5D were utilized for this logistic regression analysis in
terms of adjustment to make the mean equal to zero and
the SD equal to 1.0. The formulae for calculating stan-
dardized dNRS and dEQ-5D in each patient are
▪ (dNRS in each patient −mean of dNRS)/SD of dNRS
▪ (dEQ-5D in each patient −mean of dEQ-5D)/SD of
dEQ-5D
A two-sided p value < 0.05 was considered statistically
significant. All statistical analyses were performed using
R version 3.2.1 (Foundation for Statistical Computing,
Vienna, Austria) and JMP 9.0 (SAS Institute Japan Ltd.
Tokyo, Japan).
Results
Descriptive analysis of demographics
Data from a total of 710 patients with complete EQ-5D,
NRS, and PGI at baseline and Week 4 were retrieved and
classified into the post hoc analysis set. Table 1 presents
the demographics of these patients. The mean age was
66.7 (SD, 14.4) years and a majority of patients were
women (61.7 %). The mean duration of pain symptoms
was 2.0 (3.4) years, the mean NRS score at baseline was
7.1 (1.9), and the mean EQ-5D utility score was 0.5 (0.2).
Patients were frequently diagnosed with a musculoskel-
etal/orthopedic disorder, and postherpetic neuralgia
(PHN) was included as typical neuropathic pain (Table 1).
Mean change from baseline and correlations
Table 2 summarizes the mean change from baseline in
NRS and EQ-5D at 4 weeks after treatment. The mean ±
SD dNRS and dEQ-5D from baseline were −2.7 ± 2.3 points
(paired t-test, p < 0.001) and 0.16 ± 0.20 points (pairedt-test, p < 0.001), respectively. Larger mean dNRS was
observed in lumbago (−2.9) and osteoarthritis (−2.9),
whereas a relatively smaller change was observed in
rheumatoid arthritis (−1.7). The largest improvement of
EQ-5D was observed in patients with lumbago (0.19),
and the smallest improvement was observed in those
with rheumatoid arthritis (0.10). The proportion of pa-
tients with PGI assessed as “effective” was 86.1 %
(95 % CI, 83.9–88.3) at Week 4.
Table 3 presents the correlation between absolute
dNRS and dEQ-5D. Significant correlations were ob-
served between the two scores (Fig. 1, Table 3). There
was a relatively close negative correlation between the
dNRS and dEQ-5D at Week 4, with a correlation coeffi-
cient (r) of 0.53 (p < 0.0001). The simple linear regres-
sion model indicated that for each 1-point reduction in
Table 2 PGI and mean changes from baseline in NRS and EQ-5D utility scores
n PGI
Effective
dNRS Week 4 (Δ) p dEQ-5D Week 4 (Δ) p
Baseline Week 4 (Δ) Baseline Week 4 (Δ)
Overall 710 614 (86.5) 7.1 [1.9] −2.7 [2.3] <0.0001 0.51 [0.20] 0.16 [0.20] <0.0001
Major the causal disease of pain (multiple allowed)
Osteoarthritis 182 168 (92.3) 7.0 [2.0] −2.9 [2.3] <0.0001 0.53 [0.15] 0.17 [0.19] <0.0001
Lumbago 285 253 (88.8) 7.4 [1.8] −2.9 [2.4] <0.0001 0.47 [0.23] 0.19 [0.22] <0.0001
Rheumatoid arthritis 29 21 (72.4) 6.4 [2.1] −1.7 [2.0] 0.0002 0.51 [0.18] 0.10 [0.15] 0.0018
Neck, shoulder and arm syndrome 44 38 (86.4) 7.5 [1.7] −2.8 [2.2] <0.0001 0.61 [0.14] 0.12 [0.18] <0.0001
Postherpetic neuralgia 54 46 (85.2) 6.7 [2.1] −2.9 [2.1] <0.0001 0.58 [0.17] 0.15 [0.16] <0.0001
Periarthritis scapulohumeralis 46 39 (84.8) 7.4 [1.8] −2.2 [1.7] <0.0001 0.55 [0.13] 0.12 [0.16] <0.0001
Spinal stenosis 61 47 (77.0) 7.1 [2.0] −2.5 [2.6] <0.0001 0.53 [0.10] 0.12 [0.16] <0.0001
Disk herniation 30 27 (90.0) 6.8 [1.8] −2.7 [2.4] <0.0001 0.50 [0.19] 0.17 [0.20] <0.0001
Others 233 196 (84.1) 6.9 [2.0] −2.5 [2.6] <0.0001 0.52 [0.18] 0.13 [0.20] <0.0001
dEQ-5D denotes change in EuroQol-5D, dNRS change in numeric rating scale, PGI physician’s global impression
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(m). When stratified by causal disease, none of the
groups showed zero slope, but the lumbago, rheumatoid
arthritis, and PHN subgroups showed smaller Pearson
correlations (r < 0.5).
Estimated MCIC of dEQ-5D, dNRS, and achievement ratio
of MCIC
The overall MCIC of ROC analysis based on PGI showed
a cutoff point of −2.0 points (AUC = 0.88, sensitivity =
0.77, specificity = 0.88) for dNRS; for dEQ-5D, it was 0.10
(AUC= 0.88, sensitivity = 0.64, specificity = 0.90) (Figs. 2
and 3). The specificity of both of dNRS and dEQ-5D were
similar but the sensitivity of dNRS was higher than dEQ-
5D. The ratio of MCIC achievement and PGI “effective”Table 3 Correlation Between dEQ-5D Utility Score (y) and dNRS
Δ (x) by Causal Disease




Overall 710 −0.045 0.531 <0.0001
Major the causal disease
of pain (multiple allowed)
Osteoarthritis 182 −0.044 0.542 <0.0001
Lumbago 285 −0.042 0.457 <0.0001
Rheumatoid arthritis 29 −0.037 0.498 0.0060
Neck, shoulder and
arm syndrome
44 −0.046 0.552 0.0001
Postherpetic neuralgia 54 −0.037 0.468 0.0004
Periarthritis scapulohumeralis 46 −0.057 0.619 <0.0001
Spinal stenosis 61 −0.041 0.660 <0.0001
Disk herniation 30 −0.057 0.698 <0.0001
Others 233 −0.046 0.601 <0.0001
dEQ-5D denotes change in EuroQol-5D, dNRS change in numeric rating scaleclassification are shown in Table 4. In total, 405 (57.0 %)
patients had improved EQ-5D ≥ 0.10 points, whereas 487
(68.6 %) patients had improved NRS ≥ 2.0 (Table 4).
Coefficient of NRS and EQ-5D to PGI judgment
Logistic regression analysis by using standardized dNRS
and dEQ-5D as covariates was conducted to further in-
vestigate the impact of dNRS and dEQ-5D on PGI judg-
ment. The absolute value of standardized coefficient is
compatible between the dNRS and dEQ-5D, and the co-
efficient of NRS was higher (−1.490, p < 0.001) than the
coefficient of EQ-5D (0.795, p < 0.001).
Discussion
In our study population, the most common cause of
pain was musculoskeletal disorders. In a majority of pa-
tients, baseline NRS scores corresponding to pain inten-
sity could be qualified as moderate-to-severe pain. While
Nawata et al. had reported an average EQ-5D utility
score of 0.83 (95 % CI, 0.82–0.84; n = 2937) in Japanese
elderly (mean age, 72.3 [SD, 6.1] years) volunteers [19],
the mean EQ-5D utility score at baseline in our study
population (mean age, 66.7 [SD, 14.4] years) was remark-
ably lower (0.51 [SD, 0.20])
In general, pain intensity scores are associated with
QOL scale in pain disorders [6, 20, 21]. In our results, a
significant correlation (r = 0.53, p < 0.001) was observed
between dNRS and dEQ-5D scores, and both dNRS and
dEQ-5D supported the treatment effect of tramadol/
acetaminophen therapy. The simple linear regression
model indicated that a 1-point reduction in dNRS corre-
sponded to a 0.045-point improvement in dEQ-5D. This
conversion ratio may be applicable to clinical practice
for chronic pain management when practitioners evalu-
ate clinical outcomes using the NRS or EQ-5D scales.
However, there is a possibility that other factors strongly
Fig. 1 Correlation between dNRS (ΔNRS) and dEQ-5D utility score (ΔEQ-5D)
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ample, an individual patient who had severe side effects
would result in a deterioration of QoL. Therefore we
need to evaluate QoL and functionality along with pain
severity in the treatment of chronic pain patients.
The primary aim of this study was to estimate the OCP
for MCIC of the NRS and the Japanese version of EQ-5D,
with an emphasis on noncancer chronic pain using simple
and conventional statistical analysis methods. The OCP of
MCIC was estimated to be a 0.10-point increase in EQ-
5D and a 2.0-point reduction in NRS.
Two-thirds of physicians have agreed on an OCP of 2-
to 4-point reduction in NRS scores as the MCIC [22].
Salaffi et al. reported a 2-point reduction in NRS as
the minimal treatment target for chronic pain [10].
The mean change in the pain intensity score from baseline
by using a 10-mm visual analog scale at 4 weeks
after tramadol/acetaminophen therapy was −22.35 mm
(SD, 21.19) in the clinical registration trial in Japanese pa-
tients with chronic noncancer pain [23]. These results
support that the MCIC of NRS we propose is clinically
relevant in the Japanese population. In addition, several
reports have suggested a minimal clinically important dif-
ference in EQ-5D utility score as approximately 0.08 [7] toFig. 2 ROC curve of PGI and change from baseline NRS (dNRS)0.17 [8] in the treatment of low back pain. The results of
our study that used Japanese real-world data are consist-
ent with these previous reports. We identified an MCIC
that is clinically comparable to that derived from medical
research conducted in multi-countries and that may
provide the reasonable minimum treatment target for
Japanese patients with chronic pain in real-world practice.
The distribution-based approach using one- half of stand-
ard deviation at baseline value was frequently used to de-
termine the OCP of MCIC [24]. In this study, one- half of
standard deviation at baseline of EQ-5D was 0.1 (Table 2)
that was same as OCP of MCIC produced by the anchor-
based approach using PGI. We did not see the discrepancy
between the conclusions of both approaches. As a limita-
tion of our result, the estimated MCICs were based on the
analysis of complete data at baseline and week 4. We as-
sumed missing at random for missing data mechanism
and no imputation for missing data has been performed.
The PGI (effectiveness) and the rate of MCIC achieve-
ment of EQ-5D (<0.1) and NRS (< −2.0) were 86.5 %
(614/710), 57.0 % (405/710), and 68.6 % (487/710),
respectively. The rate of MCIC achievement in both
patient-reported outcomes was lower and seemed more
conservative than physician’s judgment. A larger discrepancy
Fig. 3 ROC curve of PGI and change from baseline EQ-5D (dEQ-5D)
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ratio of MCIC achievement in EQ-5D than in NRS. In
addition, logistic regression analysis using standardized
dNRS and dEQ-5D suggested that improvements in
both the NRS score (p < 0.001) and the EQ-5D utility
score (p < 0.001) were independently associated with a
more favorable PGI judgment. The absolute value of
the standardized coefficient was compatible between
dNRS and dEQ-5D, but the coefficient of dNRS was
higher (−1.490) than the coefficient of dEQ-5D (0.795),
suggesting that physician’s judgment is influenced
more by changes in NRS scores than by changes in
EQ-5D utility scores. This result was consistent with
the result of ROC analysis that the sensitivity of OPC
of MCIC on dNRS was higher than dEQ-5D. This may
suggest that when judging improvement, physicians
should consider improvements in pain severity than
improvements in the patient’s QoL.Table 4 Rate of MCIC Achievement
PGI Effective NRS≤ −2 EQ-5D≥ 0.10
Overall 614 (86.5) 487 (68.6) 405 (57.0)
Major the causal disease
of pain (multiple allowed)
Osteoarthritis 168 (92.3) 130 (71.4) 113 (62.1)
Lumbago 253 (88.8) 214 (75.1) 177 (62.1)
Rheumatoid arthritis 21 (72.4) 18 (62.1) 13 (44.8)
Neck, shoulder and
arm syndrome
38 (86.4) 32 (72.7) 22 (50.0)
Postherpetic neuralgia 46 (85.2) 39 (72.2) 30 (55.6)
Periarthritis scapulohumeralis 39 (84.8) 33 (71.7) 21 (45.7)
Spinal stenosis 47 (77.0) 37 (60.7) 26 (42.6)
Disk herniation 27 (90.0) 18 (60.0) 17 (56.7)
Others 196 (84.1) 142 (60.9) 112 (48.1)
EQ-5D denotes EuroQol-5D, MCIC minimal clinically important change, NRS
numeric rating scale, PGI physician’s global impressionConclusion
The post treatment changes from baseline in NRS scores
and Japanese version of EQ-5D utility scores were well
correlated in Japanese patients with chronic noncancer
pain. Simple ROC using the PGI-anchored approach es-
timated a 0.10-point increase as the OCP of MCIC in
EQ-5D utility scores and a 2.0-point reduction in NRS
scores. Our results demonstrated novel cutoff criteria for
the Japanese version of EQ-5D, focusing on patients with
chronic noncancer pain. The obtained criteria were fairly
consistent and could be utilized as an evaluation tool in
medical research on noncancer chronic pain in Japan,
providing additional functionality and usability for QoL
assessment in pain management practice. The EQ-5D
scale is a useful evaluation tool for QoL assessment in
real-world treatment of Japanese patients with chronic
noncancer pain.
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